{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=75", "query": { "condition": "Melanoma Neoplasms", "page": 75 }, "page_size": 10 }, "pagination": { "page": 75, "page_size": 10, "total_count": 2209, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=76&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=74&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T15:41:56.271Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05717140", "title": "Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Malignant Neoplasm in the Lung", "Metastatic Melanoma", "Recurrent Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Aerosol Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-10-28", "completion_date": "2026-01-28", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717140" }, { "nct_id": "NCT00104988", "title": "S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2005-06", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-08-22", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 132, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Castro Valley, California + 89 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fairfield", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104988" }, { "nct_id": "NCT04657991", "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2021-01-15", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 27, "location_summary": "Orlando, Florida • Fairway, Kansas • Overland Park, Kansas + 16 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657991" }, { "nct_id": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Melanoma", "Advanced Solid Tumor, Adult", "Metastatic Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-11-21", "completion_date": "2023-03-18", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 9, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729596" }, { "nct_id": "NCT03291288", "title": "Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potential" ], "interventions": [ { "name": "Tolbutamide", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Pexidartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2018-02-26", "completion_date": "2021-04-16", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291288" }, { "nct_id": "NCT00790010", "title": "Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Bevacizumab Plus Ipilimumab Cohort 1", "type": "DRUG" }, { "name": "Bevacizumab Plus Ipilimumab Cohort 2", "type": "DRUG" }, { "name": "Bevacizumab Plus Ipilimumab Cohort 3", "type": "DRUG" }, { "name": "Bevacizumab Plus Ipilimumab Cohort 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2009-02-26", "completion_date": "2018-06-22", "has_results": false, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790010" }, { "nct_id": "NCT00162123", "title": "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2006-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-07-27", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 19, "location_summary": "Tucson, Arizona • Laverne, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Laverne", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00162123" }, { "nct_id": "NCT04987996", "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "GR-MD-02", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-07-01", "completion_date": "2031-07-01", "has_results": false, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04987996" }, { "nct_id": "NCT00072124", "title": "Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2003-09", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072124" }, { "nct_id": "NCT04205227", "title": "ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Melanoma", "Ovary Cancer", "Pancreatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "ENB003", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ENB Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 137, "start_date": "2020-02-18", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-03T15:41:56.271Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04205227" } ] }